Approval

Hengrui wins China approval for SHR-1918, first local ANGPTL3 antibody, in HoFH

Chinese regulators approved SHR-1918 for patients aged 12 and up with homozygous familial hypercholesterolemia. In a phase 3 trial of 54 patients, LDL cholesterol dropped 58.8% at week 12 versus a 5.5% rise on placebo, with the effect holding to week 24. Most side effects were mild.

Written by Gosset from public sources. Source types: SEC/exchange filing · News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call